Study of Calgranulin A/B Levels in Patients With Newly Diagnosed Stage I,II,III Breast Cancer

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Measuring levels of calgranulin A and calgranulin B in the blood of patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to breast cancer. PURPOSE: This laboratory study is measuring calgranulin A and calgranulin B levels in the blood of patients with newly diagnosed stage I, stage II, or stage III breast cancer.

Detailed Description
-----------------
OBJECTIVES: Determine circulating levels of calgranulin A and calgranulin B in patients with estrogen receptor negative or estrogen receptor positive, newly diagnosed, primary stage I-III adenocarcinoma of the breast. OUTLINE: This is a pilot study. Patients undergo a blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B. Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression. PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.

Official Title
-----------------
A Pilot Trial to Correlate Serum Levels of Calgranulin A and B With Estrogen Receptor Status Among Patients With Breast Cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: immunoenzyme technique
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically confirmed primary adenocarcinoma of the breast Stage I-III disease No evidence of metastatic disease Newly diagnosed disease Hormone receptor status: Estrogen receptor-positive- or -negative tumor PATIENT CHARACTERISTICS: Sex Not specified Menopausal status Not specified Performance status Not specified Life expectancy Not specified Hematopoietic Not specified Hepatic Not specified Renal Not specified Other Not pregnant No Crohn's disease No arthritis No psoriasis No lupus erythematosus No multiple sclerosis No other severe active inflammation Not C-reactive protein positive No HIV positivity No other serious medical or psychiatric illness PRIOR CONCURRENT THERAPY: Radiotherapy No prior radiotherapy for breast cancer Surgery No prior organ transplantation Other No prior systemic therapy for breast cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.|
|Other: laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between circulating levels of calgranulin A and calgranulin B and the presence of estrogen receptor negative breast cancer |  | upon diagnosis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage I breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer